No Carolina / NY / Florida
Ph: 561.316.3330

No Carolina | NY | Florida

Zhengxin Group Donates 1.5 Mil Boxes of Masks to Cities in China

Editor: What To Know

  • “For more than 10 years, Zhengxin has been one of the cooperative suppliers of the Chinese government’s national strategic material reserve, and we are honored to have the opportunity to contribute to the fight against COVID-19, which is our corporate social responsibility,”.
  • The mask donation is a manifestation of the performance of Zhengxin Group’s high-efficiency production model through the introduction of fully automated mask production machines in November.
  • However, within the first days of the new policy, new cases surged to over 50,000 per day, causing a massive rise in the demand for face masks.

On December 10, 2022, Zhengxin Group, a leading personal protective equipment (PPE) manufacturer headquartered in mainland China, announced that they have donated over 1.5 million boxes of masks to various cities within China. The donation aims to help ease the effects of the COVID-19 pandemic following the lifting of lockdowns by the Chinese government in early December.

The new policy in China allows citizens across China to move freely for the first time since the pandemic started in early 2020. However, within the first days of the new policy, new cases surged to over 50,000 per day, causing a massive rise in the demand for face masks.

Zhengxin Group is preparing to donate a warehouse of 1.5 million boxes of masks

“For more than 10 years, Zhengxin has been one of the cooperative suppliers of the Chinese government’s national strategic material reserve, and we are honored to have the opportunity to contribute to the fight against COVID-19, which is our corporate social responsibility,” CEO of Zhengxin Group Danny Peng said. “We have been committed to providing reliable security protection for medical workers around the world, and creating value for our suppliers and employees.”

The mask donation is a manifestation of the performance of Zhengxin Group’s high-efficiency production model through the introduction of fully automated mask production machines in November. Zhengxin will continue to invest in research and development technology to develop high-capacity production equipment to prepare for the next possible virus.

The hightened demand for coverings emptied face masks from pharmacies across the county. In response, Zhengxin Group announced that it will donate 1.5 million boxes of masks from its existing safety stock to various places in China with Beijing, Shanghai and Shenzhen accounting for 45% of the total donations.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Recent News

CV Societies Propel Plans Forward for a New Board of Cardiovascular Medicine

“The open comment period is the time for cardiovascular physicians, allies in other medical specialties, patients, and others to make their voices heard on why an independent CV Board is the best path for cardiologists to stay up-to-date on best practices and evidence-based care, ensuring patients receive the best possible care,” said Jeffrey Kuvin, MD, president of the proposed Board’s new Board of Directors. “The field of cardiovascular medicine has evolved dramatically over the past few decades; now is the right time to develop an independent cardiovascular Board.”

Hyundai Bioscience Announces Clinical Development Plan for Niclosamide-based Metabolic Anticancer Drug Targeting P53 Mutation Cancer

Sang-ki Oh, CEO of Hyundai Bioscience, stated, "Niclosamide-based metabolic anticancer drug candidate will be the first P53-targeting anticancer treatment that selectively kills p53 mutated cancer cells," and added, "Through our subsidiary ADM Korea, we plan to conduct clinical trials targeting cancer patients with intractable cancer caused by p53 mutations, which will be the first step of clinical development on niclosamide-based anticancer agent pipeline."

Sedana Medical Completes Patient Recruitment for INSPiRE-ICU 1 Clinical Trial in the US

Peter Sackey further elaborated: "Once the 30-day follow-up of all patients is complete, we will enter into an intense phase of final monitoring, data cleaning and transfer to our statistician team for analysis. In parallel, the long-term outcomes at 3 and 6 months will be collected centrally by the Critical Illness, Brain Dysfunction, and Survivorship team at Vanderbilt Medical Center. With this parallel approach, we expect topline results in the autumn of this year and a swift regulatory submission in Q1, 2025".

Health / Lifestyle

Articles of Interest

Stay Connected

spot_img

About Medical Device News Magazine

About Medical Device News Magazine. A digital publication founded in 2008 located in the United States. The publication is one of the industry’s leading sources of medical device and biotech industry updates. Medical Device News Magazine is easily accessible 24/7/365 and is a fast 1, 2, 3 easy read! Our purpose is...

By using this website you agree to accept Medical Device News Magazine Privacy Policy